

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 512 • March 2015

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. and Teva Canada Limited that the shortages of Apo-Doxazosin 1 mg Tablet (DIN 02240588) and Teva-Doxazosin 1 mg Tablet (DIN 02242728) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective March 26, 2015**.

DOXAZOSIN MESYLATE

1 MG (BASE) ORAL TABLET

00002240588	APO-DOXAZOSIN	APX	\$ 0.1416
00002240498	MYLAN-DOXAZOSIN	MYP	\$ 0.1416
00002244527	PMS-DOXAZOSIN	PMS	\$ 0.1416
00002242728	TEVA-DOXAZOSIN	TEV	\$ 0.1416
00001958100	CARDURA	PFI	\$ 0.5836

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Lorazepam 0.5 mg Sublingual Tablet (DIN 02410745), Apo-Lorazepam 1 mg Sublingual Tablet (DIN 02410753) and Apo-Lorazepam 2 mg Sublingual Tablet (DIN 02410761) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following groupings **effective March 26, 2015**.

LORAZEPAM

0.5 MG ORAL SUBLINGUAL TABLET

00002410745	APO-LORAZEPAM	APX	\$ 0.0875
00002041456	ATIVAN	PFI	\$ 0.1099

1 MG ORAL SUBLINGUAL TABLET

00002410753	APO-LORAZEPAM	APX	\$ 0.1100
00002041464	ATIVAN	PFI	\$ 0.1380

2 MG ORAL SUBLINGUAL TABLET

00002410761	APO-LORAZEPAM	APX	\$ 0.1711
00002041472	ATIVAN	PFI	\$ 0.2147

Alberta Blue Cross has been advised by Aspri Pharma Canada Inc. that the shortage of Eltroxin 0.2 mg Tablet (DIN 02213222) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective March 26, 2015**.

LEVOTHYROXINE SODIUM

0.2 MG ORAL TABLET

00002213222	ELTROXIN	APR	\$ 0.0425
00002172143	SYNTHROID	ABB	\$ 0.0857

continued on next page ...

continued from previous page ...

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Medroxy 10 mg Tablet (DIN 02277298) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective March 26, 2015**.

MEDROXYPROGESTERONE ACETATE

10 MG ORAL TABLET

00002277298	APO-MEDROXY	APX	\$ 0.1670
00002221306	TEVA-MEDROXYPROGESTERONE	TEV	\$ 0.1670
00000729973	PROVERA	PFI	\$ 0.6717

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)



®The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.512 2015/03